Sensus Healthcare

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+, and SRT-100 Vision. Its main product superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers, and other skin conditions, such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sensus Healthcare reports solid Q4 earnings, eyes growth opportunities

Sensus Healthcare's Q4 2022 earnings call highlighted strong revenue performance, strategic growth initiatives, and a focus on expense management. The company aims to leverage opportunities in technology enhancements, market expansion, and revenue growth while addressing challenges related to net income decline and managing expenses effectively.

Sensus Healthcare adapts to inflation challenges, eyes global expansion

Sensus Healthcare navigated a challenging Q1 2023 marked by inflation impacts, focusing on product demand, cost management, and international expansion to drive future growth.
Despite financial setbacks, the company's innovative SRT system, strategic initiatives, and collaborations position it well to capitalize on opportunities in the radiation oncology market and international territories.
Addressing inflation challenges, securing purchase orders efficiently, and leveraging partnerships with hospitals and pharmaceutical companies are key focus areas for Sensus Healthcare's sustainable growth strategy.

Sensus Healthcare reports Q2 growth, eyes profitability amid market challenges

Sensus Healthcare showed improved performance in Q2 but faced challenges with declining profits and negative EBITDA.
The company's strengths lie in new software introductions, marketing expansions, and AI development for product enhancement.
Opportunities include expected profitability, market recovery signs, international expansion, and investor engagement strategies.
To address challenges, Sensus needs to navigate financial pressures, regulatory hurdles, and competitive dynamics effectively.

Sensus Healthcare reports Q3 revenue decline but eyes international expansion

Sensus Healthcare faced revenue decline in Q3 but remains confident in growth prospects, emphasizing proper business management to mitigate risks.
The company's focus on international expansion and innovative clinic management solutions presents opportunities for future revenue growth and market penetration.
Despite challenges in the industry and competitive landscape, Sensus Healthcare's financial stability and strategic initiatives position it for continued success.

Sensus Healthcare excels in Q4, eyes international expansion and innovative revenue models

Sensus Healthcare's Q4 performance reflects strong sales and financial stability, positioning the company for growth.
Innovative products and new revenue models showcase the company's commitment to market expansion and revenue diversification.
While challenges exist in market expansion and cost control, strategic opportunities in international markets and new models offer avenues for growth.

Sensus Healthcare posts stellar Q1 results, eyes global expansion

Sensus Healthcare delivered outstanding results in Q1 2024, marked by robust revenue growth, operational excellence, and financial strength.
While facing challenges in maintaining growth momentum and navigating international markets, the company's strategic strengths and opportunities position it for continued success.
With a focus on innovation, market expansion, and strategic partnerships, Sensus Healthcare is poised to capitalize on its current momentum and drive future growth.

Sensus Healthcare reports stellar Q3 performance and eyes global expansion

Sensus Healthcare delivered exceptional Q3 2024 results with doubled revenues, strong profitability, and a robust balance sheet.
The company's strategic strengths include key partnerships, technology diversification, and international market progress.
While challenges like sustaining growth and managing costs exist, Sensus is well-positioned to capitalize on opportunities for expansion and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman, and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is announcing that its superficial radiation therapy SRT-100 system has shown promising results treating Cutaneous Mast Cell Tumors (MCTs) in pets. This new limited study, just published in the Journal of the American Veterinary Medical Association, demonstrates the potential effectiveness and safety of SRT treatment.

Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Kim Golodetz - Lippert/Heilshorn & Associates Joseph Sardano - Co-Founder, Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Scott Henry - ROTH Capital Chaitanya Gollakota - H.C. Wainwright Anthony Vendetti - Maxim Group Benjamin Haynor - Alliance Global Partners Operator Good afternoon and welcome to the Sensus Healthcare First Quarter 2023 Financial Results Conference Call.

Sensus Healthcare, Inc. (SRTS) Q1 2023 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.20 per share a year ago.

Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Misses Revenue Estimates

Lower demand for SRT systems reflects the impact of inflation on dermatologists' cash flow from fewer elective aesthetic procedures and higher operating costs

Sensus Healthcare Reports First Quarter 2023 Financial Results

Cellebrite DI Ltd

Innovative Solutions and Support

Wireless Telecom Group

Envela Corporation

Evolution Petroleum

Ocuphire Pharma

While the adage that you get what you pay for generally rings true, you can sometimes cheat up this narrative with the best stocks to buy under $10. While you can't get much for a Hamilton these days, you can acquire shares of surprisingly compelling enterprises.

The 7 Best Stocks Under $10 to Buy in May

MaxCyte

ProPhase Labs

Zomedica

CorMedix

Matinas BioPharma Hlds

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.

7 Small-Cap Biotech Stocks with Massive Potential

BOCA RATON, Fla. , April 25, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Wednesday, May 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host First Quarter 2023 Financial Results and Business Update Conference Call on Wednesday, May 3, 2023

Jerash holdings (US) Inc

Kornit Digital

Micron Technology

Castle Biosciences Inc

Nano-X Imaging

Opera Ltd - ADR

For investors that have the patience to ride out volatility in exchange for possible long-term upside, value stocks to buy that are discounted against book value may offer considerable intrigue. On paper, book value represents the difference between the company's total assets and total liabilities.

7 Value Stocks to Buy for Long-Term Growth

AdTheorent Holding Company Inc

Hudson Technologies

AbCellera Biologics

VAALCO Energy

Radiant Logistics

If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this.

7 Stocks to Bet On if You Want to Be Richer Than Elon Musk

New comprehensive asset and EMR management feature allows users to collect real-time information from the device to manage and maintain multiple machines with Chat GPT New comprehensive asset and EMR management feature allows users to collect real-time information from the device to manage and maintain multiple machines with Chat GPT

Sensus Healthcare announces the Sensus Cloud™; Unveils New Features at American Academy of Dermatology (AAD) Annual Meeting in New Orleans March 17-19

Sensus Healthcare quickly fell 30% after a slight miss on Q4 revenue and earnings. Actual numbers were a slight beat and only appeared to be a miss, thanks to unusual circumstances.

Sensus Healthcare: An Unjustified Earnings Selloff

Alpha Metallurgical Resources

A-Mark Precious Metals

Chimerix

International Money Express Inc.

Silicon Motion Technology

With thousands of publicly traded companies to choose from, it's inevitable that a few will make the rounds of overlooked value stocks. These enterprises represent businesses that trade at an attractive multiple to a key financial.

7 Overlooked Value Stocks That Could Outperform the Market

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q4 2022 Earnings Conference Call February 9, 2023 4:30 PM ET Company Participants Kim Golodetz - Lippert/Heilshorn & Associates Joseph Sardano - Co-Founder, Chairman & CEO Michael Sardano - President & General Counsel Javier Rampolla - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partners Alexander Nowak - Craig-Hallum Scott Henry - ROTH MKM Partners Anthony Vendetti - Maxim Group Operator Welcome to the Sensus Healthcare Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions].

Sensus Healthcare, Inc. (SRTS) Q4 2022 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -34.62% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Lag Estimates

Full-year revenues increased 65% to $44.5 million

Sensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million

The mean of analysts' price targets for Sensus Healthcare, Inc. (SRTS) points to an 81.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Sensus Healthcare, Inc. (SRTS) Have the Potential to Rally 81.12% as Wall Street Analysts Expect?

BOCA RATON, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Sensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023

Sensus Healthcare, Inc. is working to recover from a tough Q3, 2022. Preliminary Q4 2022 earnings are reigniting interest in Sensus Healthcare.

Sensus Healthcare: Better Outcomes For Painful Procedures

The consensus price target hints at a 72.6% upside potential for Sensus Healthcare, Inc. (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 72.6% Upside in Sensus Healthcare, Inc. (SRTS): Here's What You Should Know

Boeing

Caterpillar

Celsius Holdings

Chevron

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Northern Oil and Gas

Visa

Voyager Therapeutics

Two new Breakout Stocks for Week 2 with better than 10% short-term upside potential and one Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. Momentum Gauge trading signal turned positive this week and new portfolios are all positive with strong gains to start the new year.

MDA Breakout Stocks Week 2 - January 2023: High-Frequency Gainers To Give You An Edge

Haemonetics

Signify Health

Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023

How 2022's Biggest Healthcare Gainers Could Fare In 2023

Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60%

Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues

Sensus Healthcare, Inc. (SRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 46.9% in 4 Weeks, Here's Why Sensus Healthcare, Inc. (SRTS) Looks Ripe for a Turnaround

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Kim Golodetz - Investor Relations Joe Sardano - Chairman and Chief Executive Officer Michael Sardano - President and General Counsel Javier Rampolla - Chief Financial Officer Conference Call Participants Scott Henry - Roth Capital Yi Chen - H.C. Wainwright Benjamin Haynor - Alliance Global Partners Anthony Vendetti - Maxim Group Operator Hello and welcome to the Sensus Healthcare Third Quarter 2022 Earnings Conference Call.

Sensus Healthcare, Inc. (SRTS) Q3 2022 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -8.33% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Sensus Healthcare Stock (SRTS)